“EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence ” (2012) Journal of Cancer Research Updates, 1(1), pp.  102–107. doi:10.6000/1929-2279.2012.01.01.15.